Composition for use in treating retinal diseases

A technology of composition and extract, which is applied in sensory diseases, drug combinations, cardiovascular system diseases, etc., and can solve the unsatisfied problems of supplementary treatment methods and compositions for retinal diseases

Pending Publication Date: 2020-01-31
S I F I SPA
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0018] There remains an unmet need for complementary therapeutic methods and compositions for retinal diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for use in treating retinal diseases
  • Composition for use in treating retinal diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] Example 1: Composition

[0039] The compositions according to the invention are prepared as follows.

[0040] Composition A

[0041] 20 mg concentrated extract of Haematococcus containing not less than 2.0% astaxanthin

[0042] 2.5 mg dry extract obtained from the fruit of pepper with a piperine titer of 95%

[0043] 100 mg extract of the gum resin of Boswellia serrata with a total boswellic acid titer of 70% and a beta boswellic acid titer of 20%

[0044] 5mg coenzyme Q10

[0045] 50mg dry extract of the root of Curcuma longa with a total curcumin titer of 95%

[0046] 25mg progesterone titrated 20% extract of marigold flower

[0047] 0.5 mg copper (from microencapsulated copper sulfate)

[0048] 10 mg dry extract of the stigmas of Saffron crocus with a titer of 2% crocus

[0049] 10 mg zeaxanthin titer 5% marigold flower extract

[0050] Composition B

[0051] 20 mg of concentrated extract of Haematococcus containing not less than 2.0% astaxanthin

[005...

Embodiment 2

[0079] Example 2: Rat retinal ischemia-reperfusion injury model

[0080] A rat retinal ischemia-reperfusion (IR) model, widely used in the prior art as a model of acute hypertension-induced retinal degeneration, was used. Adult male Brown-Norway rats weighing approximately 200 g were orally pretreated once a day by gavage with Composition C (30 mg / day) of Example 1 or vehicle (HCV; Nuutilis, 4.25%). Pretreatment was performed for 5 days, further treatments were performed approximately one hour before induction of IR, and continued for the next 7 days. Five days after pretreatment, animals were anesthetized intraperitoneally with Zoletil (420 μ / Kg) and Atila (37 μL / Kg) solution, and after instillation of 0.5% tropicamide-induced mydriasis, the animals were treated with a 30 A caliber needle is inserted into the anterior chamber to induce IR. A stock of saline solution is placed at a certain height from the operating table, for example to ensure a hydrostatic pressure of about...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a composition comprising: astaxanthin, piperine, boswellic acids, coenzyme Q10, curcuminoids, lutein, zeaxanthin, saffron, copper and, optionally, resveratrol, bromelain, zinc, salicin and further antioxidants from natural sources. The present invention further relates to said composition for use in treating retinal diseases which are ischemic and / or degenerative in nature.

Description

technical field [0001] Described herein is a composition comprising: astaxanthin, piperine, boswellic acid, coenzyme Q10, curcuminoids, lutein, zeaxanthin, saffron, copper and optionally Resveratrol, Bromelain, Zinc, Salicin and other antioxidants of natural origin. The invention further relates to compositions for the treatment of retinal diseases which are ischemic and / or degenerative in nature. Background technique [0002] The retina is the innermost and most differentiated of the 3 tunics that make up the wall of the eyeball, extending from the optic nerve to the pupillary edge of the iris. It has the function of receiving light stimuli and converting them into neural signals that are transmitted to brain structures. [0003] Histologically, the retina consists of two layers: [0004] 1. Retinal pigment epithelium or outer leaflet [0005] 2. Neural layer or inner lobe or specifically the retina. [0006] The retina consists of several cell layers and is divided in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/88A61P9/10A61P27/02A61K36/9066A61K38/48A61K45/06A61K31/05A61K31/07A61K31/122A61K31/125A61K31/4525A61K36/02A61K36/28A61K36/324A61K36/67A61K36/704
CPCA61K31/05A61K31/07A61K31/122A61K31/125A61K31/4525A61K33/30A61K33/34A61K36/02A61K36/28A61K36/324A61K36/67A61K36/704A61K36/88A61K36/9066A61K38/4873A61K45/06A61P9/10A61P27/02A61K2300/00
Inventor 马尔切洛·桑托科诺曼努埃拉·桑托诺奇托克里斯蒂纳·扎普拉卢卡·罗萨里奥·拉·罗萨弗兰切斯科·朱利亚诺马里亚·格拉齐亚·马佐内
Owner S I F I SPA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap